Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.27 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (neuroendocrine cells) | 0.10 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1523
Sealed predictions
- GLYATL3 in dopamine neurons, braak+0.87 (p 0.002) → +0.52 (p 0.151)receipt 1530
Swarm cases
receipt 1530: GLYATL3 in dopamine neurons, braak
- power
- full sample +0.65 (p 0.0033, n 18), 95% CI +0.27 to +0.86. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.64 (p 0.0040, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.69 (p 0.0014, n 18). not the mix.
- skeptic
- leave-one-out range +0.61 to +0.76, sign flips 0; without severely affected donors +0.65 (p 0.0033, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GLYATL3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts